

pubs.acs.org/OrgLett

# Ruthenium Metathesis: A Key Step To Access a New Cyclic Tetrasubstituted Olefin Platform

Clément F. Heinrich, Didier Durand, Jérôme Starck,\* and Véronique Michelet\*



**ABSTRACT:** An rapid and mild synthetic route for the preparation of cyclic tetrasubstituted platforms via ruthenium-catalyzed ring-closing metathesis (RCM) has been developed. This process tolerates a wide range of functionalities such as nitrogen, oxygen, sulfur, silicon, and carbon tethered groups, as well as very challenging fluorine and boron atoms (36 derivatives, up to 96%). This diversity-oriented method was further demonstrated by the postfunctionalization reactions, such as Pd-couplings, *N*-substitution, and reductive amination introducing a morpholine moiety.

hrough the past decades, ruthenium catalysis has emerged as a powerful tool to construct complex structures.<sup>1</sup> Among them, Ring Closing Metathesis (RCM) has been recognized as a versatile and powerful tool in organic chemistry to synthesize small, medium, or large rings.<sup>2</sup> The synthesis of cyclic polysubstituted olefins can be achieved using Grubbs, Hoveyda-Grubbs, or tailormade catalysts, depending on the substitution pattern of the alkene.<sup>3</sup> Whereas several studies have been published on di- and trisubstituted alkenes, relatively few studies have been done on cyclic tetrasubstituted olefins.<sup>1e,4,5</sup> Considering our interest for diversity-oriented synthesis (DOS)<sup>6</sup> and atom-economical metal-catalyzed reactions' as well as tetrahydropyridine cores as key building blocks for medicinal chemistry<sup>8</sup> (Figure 1), we anticipated that readily available and functionalized diene derivatives may be suitable substrates for Ru-catalyzed metathesis. We wish, therefore, to report therein our preliminary results on the general, rapid, and unprecedented synthesis of an original and functionalized tetrasubstituted cyclic olefin platform bearing other substituents than the vic-dimethyl moiety. Some preliminary postfunctionalization transformations are also presented.

To examine the possibilities of access to tetrahydropyridine and other oxygen, carbon, sulfur, and silicon cores via-Rucatalyzed metathesis, a wide range of dienes 1 (36 derivatives) were prepared as summarized in Figure 2. A simple two-step synthesis of substrates 1 bearing  $R^1 = CO_2Me$  has been developed, starting from commercially available methyl *N*-(diphenylmethylene)glycinate and methylallyl bromide (see



Figure 1. Tetrahydropyridine and cyclohexene cores in bioactive compounds.

Supporting Information).<sup>9</sup> For phenyl- and methyl-substituted derivatives in the  $R^1$  position of 1, an alkylation of sulfones, readily accessible from the corresponding aldehydes, by methylallyl magnesium chloride yielded the corresponding carbamates,<sup>10</sup> which were submitted in an *N*-alkylation

Received: April 17, 2020







reaction.<sup>11</sup> We gained interest to functionalize the olefin by introducing several heteroatoms. Over the years, it has become clear that fluorine substituents could display a positive effect on pharmacokinetic and pharmacodynamic properties of potential drugs due to their specific chemical, biological, and physical properties.<sup>12</sup> In spite of their interesting features, to date, only scarce examples have been disclosed on metathesis reactions on fluoroalkene derivatives limited mainly to the synthesis of trisubstituted fluoro-olefins.<sup>3u,13</sup> We therefore prepared 1k-10, bearing a fluoride or trifluoromethyl group, according to nucleophilic substitution with the corresponding allylic bromide derivatives. We also turned our attention to the reactivity of a wide series of heteroatom-tethered dienes 2-5, which were synthesized according to known methodologies (see Supporting Information).<sup>11</sup> Methylmalonate derivatives 6 were also easily prepared, as well as sulfonamide derivatives 7.

Having in hand a wide range of functionalized dienes (36 congeners), we further utilized them in ring closing metathesis cyclizations (Schemes 1, 2, and 3). Nitrogen-tethered dienes



**1a-g** have been successfully cyclized in toluene (0.04 M) using  $2 \times 5$  mol % of Grubbs II catalyst, which allowed the formation of new tetrahydropyridines with good to excellent yields (Scheme 1). A bulky group, such as a TBS-hydroxymethyl group, was tolerated (**8e-g**). The RCM reaction was also feasible starting from an acrylate **1h** with 65% even if this reaction took a longer time (24 h).



Letter



Scheme 3. RCM of Compounds 7a-c and Pinacol Boranes Derived from 7a and 6e



The use of vinyl bromide derivative 1i led to no observable conversion with either Grubbs II and Hoveyda–Grubbs catalysts, in accordance to Dorta and co-workers.<sup>14</sup> To our delight, fluorinated olefins 1j-1 underwent a cyclization process with the Hoveyda–Grubbs II catalyst ( $2 \times 5 \mod \%$ ) affording the fluorinated cyclic olefin 8j-1 with good yields (72-88%). Trifluoromethylated tetrahydropyridines 8m-o could be obtained as well (56-84%) using the same conditions, but with longer reaction times (24 h). A significant decrease in yield has been observed with the ester derivative 8m (56% yield).<sup>15</sup> High yields were also observed for tetrahydropyridines 8p-q (75 and 79%).<sup>16</sup>

We then turned our attention to oxygen-, silicon-, sulfur-, and carbon-tethered dienes and were pleased to see that the Ru-catalyzed metathesis reactions of these derivatives were also feasible (Scheme 2). The *vic*-dimethyl cyclic olefin arising from ethers 2a, sulfones 5a, silyl 4a, and malonate derivatives 6a could be obtained with excellent yields (93–95%), comparable to those obtained with NBoc protected tetrahydropyridines 1a-c (86–92%). Sulfide 3 did not cyclize under these conditions.<sup>17</sup> Interestingly, the TBS-hydroxymethyl group was still tolerated, giving access to heterocycles  $9b^{16}$  and 12b-13bwith good yield (93–96%), comparably to those obtained for tetrahydropyridines 1e-g (80–92%).

When the olefin was functionalized by a fluorine or a trifluoromethyl group, malonate-tethered dienes were tolerated and the cyclohexenes 13c and 13d were isolated in 71% and 63% yields, respectively. Sulfone 5c and ethers 2c-d were

found unreactive under these conditions (Scheme 2). Considering the nonreactivity of 1i, we turned our attention to the reaction of chloro and bromo sulfonamides 7a-b (Scheme 3, eq 1).<sup>18</sup> Pleasingly, whereas the bromo derivative 7a was unreactive, the chloro derivative 7b reacted nicely, leading to the cyclic derivative 14b in moderate 55% yield.<sup>1</sup> Vinyl enol ether 7c was also subsequently engaged in an RCM reaction,<sup>20</sup> leading remarkably to the corresponding tetrahydropyridine 14c with 43% yield.<sup>19b</sup> In the pursuit of our effort to gain more diversity, a pinacol borane derivative was considered.<sup>21</sup> We chose to start from vinyl bromide 7a or 6e by a classical Miyaura borylation reaction.<sup>22</sup> But all our attempts to isolate pinacol boranes were found to be unsuccessful. So we decided to perform a tandem borylation/RCM reaction, which was able to afford the desired stable pinacol borane 15a with a fair yield of 68% over two steps. This methodology was also applied to the malonate derivative **6e** forming the pinacol borane **15b** in 75% yield (Scheme 3, eq 2).

Finally, to further illustrate the synthetic utility of such a platform, we chose to perform some post-transformations of the corresponding cyclic aminocyclohexene derivatives (Scheme 4). Palladium-catalyzed Suzuki cross-couplings have

### Scheme 4. Postfunctionalization Reactions



been achieved, starting from vinyl chloride  $14b^{22}$  or pinacol borane 15a,<sup>23</sup> giving access to product 16a-b. We illustrated the complementarity of having the halogen- or boronfunctionalized derivative, giving rise to similar isolated yields for both methods employed (Scheme 4, eq 1). An acidic deprotection on 8c could be followed by a classical peptidic coupling, leading to amide 17 in 72% isolated yield (Scheme 4, eq 2). A tandem DIBAL reduction/reductive amination could afford pharmacophores 18a-b in 40–42% yields for the twostep synthesis (Scheme 4, eq 3).

In conclusion, we have therefore extended the methodology of the ruthenium-catalyzed metathesis reactions by studying its applications and opportunities to prepare tetrasubstituted dienes. A practical route for the preparation of cyclic tetrasubstituted olefins was proposed in the presence of Grubbs II or Hoveyda–Grubbs II catalysts giving rise to a rapid access to functionalized platforms. Various carbon- and heteroatom-tethered dienes were tolerated such as oxygen, sulfone, silane, or malonate derivatives, and this protocol also allowed the formation of fluoro- or trifluoromethyl derivatives. We have also carried out various preliminary postfunctionalization reactions over the tetrahydropyridine scaffolds, leading to interesting building blocks. Further studies will focus on practical and industrial applications of this straightforward and diversity-oriented process.

## ASSOCIATED CONTENT

## Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.0c01344.

Experimental procedure and analytical data (PDF) <sup>1</sup>H and <sup>13</sup>C spectra for all new compounds (PDF)

## AUTHOR INFORMATION

# **Corresponding Authors**

- Jérôme Starck Institut de Recherches Servier, 78290 Croissy-Seine, France; Email: jerome.starck@servier.com
- Véronique Michelet Institut de Recherche de Chimie Paris, 75005 Paris, France; Institut de Chimie de Nice, 06100 Nice, France; orcid.org/0000-0002-2217-9115; Email: veronique.michelet@univ-cotedazur.fr

# Authors

- Clément F. Heinrich Institut de Recherche de Chimie Paris, 75005 Paris, France
- **Didier Durand** Institut de Recherches Servier, 78290 Croissy-Seine, France

Complete contact information is available at:

https://pubs.acs.org/10.1021/acs.orglett.0c01344

## Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

This work was supported by the Ministère de l'Education et de la Recherche and the Centre National de la Recherche Scientifique (CNRS). C.F.H. is grateful to the Institut de Recherches Servier for a grant. The authors thanks Pr. F. Goutenoire (Le Mans, France) for residual ruthenium quantification.

#### REFERENCES

(1) (a) Ruthenium in Organic Synthesis; Murahashi, S.-I., Ed.; Wiley-VCH Verlag Gmbh: Weinheim, 2004. (b) Trost, B. M.; Toste, F. D.; Pinkerton, A. B. Chem. Rev. 2001, 101, 2067. (c) Naota, T.; Takaya, H.; Murahashi, S.-I. Chem. Rev. 1998, 98, 2599. (d) Ruthenium in Catalysis; Dixneuf, P. H., Bruneau, C., Eds.; Springer: 2014. (e) Mukherjee, N.; Planer, S.; Grela, K. Org. Chem. Front. 2018, 5, 494. (f) Handbook of Metathesis, 2nd ed.; Grubbs, R. H., Wenzel, A. G., O'Leary, D. J., Khosravi, E., Eds.; Wiley-VCH Verlag Gmbh: Weinheim, 2015.

(2) Selected books and review: (a) Handbook of Metathesis: Catalyst Development; Grubbs, H. G., Ed.; Wiley-VCH Verlag Gmbh: Weinheim, 2003. (b) Alkene Metathesis in Organic Synthesis; Fürstner, A., Ed.; Springer: 1998. (c) Ogba, O. M.; Warner, N. C.; O'Leary, D. J.; Grubbs, R. H. Chem. Soc. Rev. 2018, 47, 4510. (d) Hughes, D.; Wheeler, P.; Ene, D. Org. Process Res. Dev. 2017, 21, 1938. (e) Fürstner, A. Chem. Commun. 2011, 47, 6505. (f) Cheng-Sánchez, I.; Sarabia, S. Synthesis 2018, 50, 3749.

(3) (a) Fu, G. C.; Grubbs, H. G. J. Am. Chem. Soc. 1992, 114, 5426.
(b) Fu, G. C.; Nguyen, S. T.; Grubbs, R. H. J. Am. Chem. Soc. 1993, 115, 9856.
(c) Grubbs, R. H.; Miller, S. J.; Fu, G. C. Acc. Chem. Res. 1995, 28, 446.
(d) Schmalz, H.-G. Angew. Chem., Int. Ed. Engl. 1995,

34, 1833. (e) Schuster, M.; Blechert, S. L. Angew. Chem., Int. Ed. Engl. 1997, 36, 2036. (f) Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413. (g) Fürstner, A. Top. Organomet. Chem. 1998, 1, 37. (i) Schrock, R. R. Top. Organomet. Chem. 1998, 1, 1. (i) Schrock, R. R. Tetrahedron 1999, 55, 8141. (j) Blechert, S. Pure Appl. Chem. 1999, 71, 1393. (k) Wright, D. L. Curr. Org. Chem. 1999, 3, 211. (l) Maier, M. E. Angew. Chem., Int. Ed. 2000, 39, 2073. (m) Fürstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012. (n) Roy, R.; Das, K. Chem. Commun. 2000, 519. (o) Schrock, R. R.; Hoveyda, A. H. Angew. Chem., Int. Ed. 2003, 42, 4592. (p) Deiters, A.; Martin, S. F. Chem. Rev. 2004, 104, 2199. (q) Schrock, R. R. Angew. Chem., Int. Ed. 2006, 45, 3748. (r) Grubbs, R. H. Angew. Chem., Int. Ed. 2006, 45, 3760. (s) Samojłowicz, C.; Grela, K. Chem. Rev. 2009, 109, 3708. (t) Vougioukalakis, G. C.; Grubbs, R. H. Chem. Rev. 2010, 110, 1746. (u) Guérin, D.; Gaumont, A.-C.; Dez, I.; Mauduit, M.; Couve-Bonnaire, S.; Pannecoucke, X. ACS Catal. 2014, 4, 2374.

(4) For disubstituted cyclic olefin: See ref 3a-b. For cyclic trisubstituted olefin: (a) Chatterjee, A. K.; Grubbs, R. H. Org. Lett. **1999**, 1, 1751. (b) Chatterjee, A. K.; Sanders, D. P.; Grubbs, R. H. Org. Lett. **2002**, 4, 1939. For tetrasubstituted olefins: (c) Ackermann, L.; Fürstner, A.; Weskamp, T.; Kohl, F. J.; Herrmann, W. A. Tetrahedron Lett. **1999**, 40, 4787. (d) Liang, Y.; Raju, R.; Le, T.; Taylor, C. D.; Howell, A. R. Tetrahedron Lett. **2009**, 50, 1020. (e) White, D. E.; Stewart, I. C.; Grubbs, R. H.; Stoltz, B. M. J. Am. Chem. Soc. **2008**, 130, 810.

(5) For several articles performed on dimethyl group, see: (a) Scholl, M.; Trnka, T. M.; Morgan, J. P.; Grubbs, R. H. *Tetrahedron Lett.* **1999**, 40, 2247. (b) Fürstner, A.; Thiel, O. R.; Ackermann, L.; Schanz, H. J.; Nolan, S. P. J. Org. Chem. **2000**, 65, 2204. (c) Yao, Q.; Zhang, Y. J. Am. Chem. Soc. **2004**, 126, 74. (d) Michrowska, A.; Bujok, R.; Harutyunyan, S.; Sashuk, V.; Dolgonos, G.; Grela, K. J. Am. Chem. Soc. **2004**, 126, 9318. (e) Yao, Q.; Sheets, M. J. Organomet. Chem. **2005**, 690, 3577. (f) Berlin, J. M.; Campbell, K.; Ritter, T.; Funk, T. W.; Chlenov, A.; Grubbs, R. H. Org. Lett. **2007**, 9, 1339. (g) Stewart, I. C.; Ung, T.; Pletnev, A. A.; Berlin, J. M.; Grubbs, R. H.; Schrodi, Y. Org. Lett. **2007**, 9, 1589. (h) Rost, D.; Porta, M.; Gessler, S.; Blechert, S. *Tetrahedron Lett.* **2008**, 49, 5968. (i) Peeck, L. H.; Plenio, H. Organometallics **2010**, 29, 2761. (j) Sashuk, V.; Peeck, L. H.; Plenio, H. Chem. - Eur. J. **2010**, 16, 3983. (k) Paek, S. M. Molecules **2012**, 17, 3348.

(6) (a) Burke, M. D.; Schreiber, S. L. Angew. Chem., Int. Ed. 2004, 43, 46. (b) Diversity-Oriented Synthesis: Basics and Applications in Organic Synthesis, Drug Discovery, and Chemical Biology; Trabocchi, A., Ed.; John Wiley & Sons: New York, 2013.

(7) (a) Arcadi, A.; Chiarini, M.; Del Vecchio, L.; Marinelli, F.; Michelet, V. *Eur. J. Org. Chem.* **2017**, 2017, 2214. (b) Tomas-Mendivil, E.; Heinrich, C.; Ortuno, J.-C.; Starck, J.; Michelet, V. ACS *Catal.* **2017**, 7, 380. (c) Arcadi, A.; Chiarini, M.; Del Vecchio, L.; Marinelli, F.; Michelet, V. *Chem. Commun.* **2016**, 52, 1458. (d) Arcadi, A.; Pietropaolo, E.; Alvino, A.; Michelet, V. *Org. Lett.* **2013**, 15, 2766. (e) Mariaule, G.; Newsome, G.; Toullec, P. Y.; Belmont, P.; Michelet, V. *Org. Lett.* **2014**, 16, 4570. (f) Tang, Y.; Benaissa, I.; Huynh, M.; Vendier, L.; Lugan, N.; Bastin, S.; Belmont, P.; César, V.; Michelet, V. *Angew. Chem., Int. Ed.* **2019**, 58, 7977. (g) Chen, X.; Martini, S.; Michelet, V. *Adv. Synth. Catal.* **2019**, 361, 3612.

(8) (a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem.
2014, 57, 10257. (b) Holladay, M. W.; Dart, M. J.; Lynch, J. K. J. Med. Chem. 1997, 40, 4169. (c) Chow, K.; Heidelbaugh, T.; Nguyen, P.; Sinha, S. (Allergan Inc, USA) WO 2,007,005,177; November 1, 2007. (d) Brown, B. S.; Keddy, R.; Zheng, G. Z.; Schmidt, R. G.; Koenig, J. R.; McDonald, H. A.; Bianchi, B. R.; Honore, P.; Jarvis, M. J.; Surowy, C. S.; Polakowski, J. S.; Marsh, K. C.; Faltynek, C. R.; Lee, C. H. Bioorg. Med. Chem. 2008, 16, 8516. (e) Böttcher, H.; Barnickel, G.; Hausberg, H. H.; Haase, A. F.; Seyfried, C. A.; Eiermann, V. J. Med. Chem. 1992, 35, 4020. (f) Manning, A. S.; Chatelain, P. P. U.S. Patent 5,378,709, Jan. 3, 1995. (g) Magańa-Garcia, M.; Arista-Viveros, A. Pediatr. Dermatol. 1993, 10, 352.

(10) (a) Willumstad, T. P.; Boudreau, P. D.; Danheiser, R. L. J. Org. Chem. **2015**, 80, 11794. (b) Majhail, M. J.; Ylioja, P. M.; Willis, M. C. Chem. - Eur. J. **2016**, 22, 7879.

(11) Kuhn, K. M.; Champagne, T. M.; Hong, S. H.; Wei, W.-H.; Nickel, A.; Lee, C. W.; Virgil, S. C.; Grubbs, R. H.; Pederson, R. L. *Org. Lett.* **2010**, *12*, 984.

(12) (a) Ismail, F. M. D. J. Fluorine Chem. 2002, 118, 27.
(b) Biomedical Frontiers of Fluorine Chemistry; Ojima, I., McCarthy, J. R., Welch, J. T., Eds.; ACS Symposium Series 639; American Chemical Society: Washington, DC, 1996. (c) Welch, J. T.; Eswarakrishnan, S. Fluorine in Bioorganic Chemistry; Wiley: New York, 1991. (d) Enantiocontrolled Synthesis of Fluoro-organic Biomedical Targets; Soloshonok, V. A., Ed.; Wiley: New York, 1999.

(13) (a) Salim, S. S.; Bellingham, R. K.; Satcharoen, V.; Brown, R. C. D. Org. Lett. 2003, 5, 3403. (b) Marhold, M.; Buer, A.; Hiemstra, H.; van Maarseveen, J. H.; Haufe, G. Tetrahedron Lett. 2004, 45, 57. (c) De Matteis, V.; van Delf, F. L.; Tiebes, J.; Rutjes, F. P. J. T. Eur. J. Org. Chem. 2006, 2006, 1166. (d) De Matteis, V.; van Delf, F. L.; Jakobi, H.; Lindell, S.; Tiebes, J.; Rutjes, F. P. J. T. J. Org. Chem. 2006, 71, 7527. (e) De Matteis, V.; van Delf, F. L.; de Gelder, R.; Tiebes, J.; Rutjes, F. P. J. T. Tetrahedron Lett. 2004, 45, 959. (f) De Matteis, V.; Dufay, O.; Waalboer, D. C. J.; van Delf, F. L.; Tiebes, J.; Rutjes, F. P. J. T. Eur. J. Org. Chem. 2007, 2007, 2667. (g) De Matteis, V.; van Delf, F. L.; Tiebes, J.; Rutjes, F. P. J. T. Synlett 2008, 3, 351. (h) Marhold, M.; Stillig, C.; Fröhlich, R.; Haufe, G. Eur. J. Org. Chem. 2014, 2014, 5777. (i) Cogswell, T. J.; Donald, C. S.; Long, D. L.; Marquez, R. Org. Biomol. Chem. 2015, 13, 717. (j) Donohoe, T. J.; Fishlock, L. P.; Procopiou, P. A. Org. Lett. 2008, 10, 285.

(14) Gatti, M.; Drinkel, E.; Wu, L.; Pusterla, I.; Gaggia, F.; Dorta, R. J. Am. Chem. Soc. **2010**, 132, 15179.

(15) Hoveyda–Grubbs II catalyst did not show any activities toward the formation of tetrasubstituted cyclic fluoro- or trifluoromethylated olefins.

(16) Analysis of residual ruthenium level showed a low amount of ruthenium (4.1-5.3 ppm) for 8q and 9b (see Supporting Information).

(17) Chelation of the ruthenium complex by the sulfide or the disfavored torsion angle could be the cause of this result. See:
(a) Shon, Y. L.; Lee, T. R. *Tetrahedron Lett.* **1997**, *38*, 1283.
(b) Spagnol, G.; Heck, M. P.; Nolan, S. P.; Mioskowski, C. Org. Lett. **2002**, *4*, 1767.

(18) Dong, X.; Sang, R.; Wang, Q.; Tang, X.-Y. Chem. - Eur. J. 2013, 19, 16910.

(19) (a) Vinyl chloride **14b** was accompanied with 36% of homocoupling product. (b) Silyl enol ether **14c** was accompanied with 42% of isomerized-thermodynamic silyl enol ether and 13% of cross-metathesis product.

(20) (a) Aggarwal, V. K.; Daly, A. M. Chem. Commun. 2002, 2490.
(b) Hoshi, M.; Kaneko, O.; Nakajima, M.; Arai, S.; Nishida, A. Org. Lett. 2014, 16, 768. (c) Chao, W.; Weinreb, S. M. Org. Lett. 2003, 5, 2505. (d) Chao, W.; Meketa, M. L.; Weinreb, S. M. Synthesis 2004, 2004, 2058. (e) Korboukh, I.; Kumar, P.; Weinreb, S. M. J. Am. Chem. Soc. 2007, 129, 10342.

(21) (a) Renaud, J.; Ouellet, S. G. J. Am. Chem. Soc. 1998, 120, 7995.
(b) Morrill, C.; Funk, T.; Grubbs, R. H. Tetrahedron Lett. 2004, 45, 7733. (c) Altenhofer, E.; Harmata, M. Org. Lett. 2014, 16, 3.

(22) Thakur, A.; Zhang, K.; Louie, J. Chem. Commun. 2012, 48, 203.
(23) Rauniyar, V.; Zhai, H.; Hall, D. G. J. Am. Chem. Soc. 2008, 130, 8481.

(9) For further details, see Supporting Information.